Contains Solid Synthetic Resin Patents (Class 424/501)
  • Patent number: 11369631
    Abstract: A gelling liquid formulation comprising a thermoresponsive hydrogel modified with an agent that reduces the alters the native gelation point of the thermoresponsive hydrogel and methods for making and using the same.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: June 28, 2022
    Assignee: UMM Rainforest Innovations
    Inventors: Jason Thomas McConville, Elnaz Sadeghi
  • Patent number: 11305013
    Abstract: The invention relates to an ultrasound contrast agent (UCA) comprising an outer shell and a gas core. The gas core is filled with oxygen, and the outer shell comprises a first surfactant and a second surfactant. The invention also relates to a method of making an oxygen-filled UCA and delivering oxygen to a local area of a subject's body. The method comprises injecting a composition comprising an oxygen-filled UCA of the invention into the subject's body; directing ultrasound radiation to the local area in an intensity sufficient to rupture the UCA.
    Type: Grant
    Filed: August 25, 2015
    Date of Patent: April 19, 2022
    Assignees: Drexel University, Thomas Jefferson University
    Inventors: John Robert Eisenbrey, Margaret Alison Wheatley, Patrick O'Kane, Lorenzo Albala, Flemming Forsberg
  • Patent number: 11279933
    Abstract: The present invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of Leber congenital amaurosis.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: March 22, 2022
    Assignee: Stichting Radboud universitair medisch centrum
    Inventors: Robert Wilhelmus Johanna Collin, Franciscus Peter Maria Cremers, Antonia Ingrid Den Hollander
  • Patent number: 11253480
    Abstract: A method for treating an ocular disorder in a subject comprising administering a therapeutic agent-loaded carrier to an ocular site of the subject in need thereof, wherein the therapeutic agent is a histone deactylase inhibitor.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: February 22, 2022
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Steven R. Little, Michelle L. Ratay
  • Patent number: 11253598
    Abstract: Disclosed are a pharmaceutical composition for anionic drug delivery, and a preparation method therefor, the pharmaceutical composition for anionic drug delivery containing: an anionic drug as an active ingredient; a cationic compound; an amphiphilic block copolymer; and a polylactate, wherein the anionic drug formed a complex with the cationic lipid, and the complex is encapsulated within a micelle structure formed by the amphiphilic block copolymer and the polylactate.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: February 22, 2022
    Inventors: Hye Yeong Nam, Bong-Oh Kim, Min-Hyo Seo, Ji-Yeon Son, Ji-Hye Choi, Sang Hoon Kim
  • Patent number: 11246879
    Abstract: Methods, agents, and devices to treat medical conditions through local chemical neuromodulation of the autonomic nervous system are described. Drug formulations may be injected at or near ganglia, nerve plexi, ganglionated plexi, and nerves to treat different diseases. Target sites for the treatment of cardiac and other disease conditions may include extrinsic stellate (cervicothoracic) and cervical ganglia of the sympathetic chain, and intrinsic cardiac nerves and ganglionated plexi innervating the myocardium.
    Type: Grant
    Filed: February 9, 2017
    Date of Patent: February 15, 2022
    Assignee: Tulai Therapeutics, Inc.
    Inventors: Corinne Bright, Kondapavulur T. Venkateswara-Rao, Emily Stein
  • Patent number: 11202762
    Abstract: The present invention relates to a drug delivery system comprising a core and a shell in which the core comprises a hydrolytically degradable polymer X which polymer backbone comprises pendant ester and acid functionalities and in which the shell comprises a hydrolytic degradable polymer Y. The hydrolytic degradable polymers X and Y are different polymers. Polymer X further comprises amino-acids in the polymer backbone and degrades via zero order degradation kinetics for a period of at least 3 months. Polymer Y degrades via auto-acceleration degradation kinetics.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: December 21, 2021
    Assignee: DSM IP ASSETS B.V.
    Inventors: George Mihov, Guy Draaisma, Silvana Rensina Antonnietta Di Silvestre, Tristan Handels
  • Patent number: 11166947
    Abstract: The present invention generally relates to treating attention-deficit disorders (e.g., ADHD) by providing an effective amount of an ADHD-effective agent to a patient in need thereof (e.g., a child).
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: November 9, 2021
    Assignee: Neos Therapeutics, LP
    Inventors: Mark Tengler, Nathan Teuscher
  • Patent number: 11147904
    Abstract: An implantable medical device including at least one double-walled microsphere containing an active agent, and a biodegradable polymer layer containing the at least one double-walled microsphere.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: October 19, 2021
    Assignee: University Of Pittsburgh—Of The Commonwealth System Of Higher Education
    Inventors: Lauren Elizabeth Kokai, Kacey Gribbin Marra
  • Patent number: 11135167
    Abstract: Biodegradable, cross-linked polymer particle embolics and methods of making the same are described. The particle embolics can be used as embolization agents.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: October 5, 2021
    Assignee: Terumo Corporation
    Inventors: Gregory M. Cruise, Gloria Hincapie, Clayton Harris
  • Patent number: 11118016
    Abstract: Provided herein are dendrimers comprising: a core unit, five generations of building units which are lysine residues or analogues thereof, first terminal groups comprising a cabazitazel residue covalently attached to a diglycolyl linker group, and second terminal groups comprising a PEG group. Also provided herein are pharmaceutical compositions comprising the dendrimers, and methods and uses of the dendrimers in therapy of disorders such as cancers. Processes for making the dendrimers and intermediates are also provided.
    Type: Grant
    Filed: August 26, 2020
    Date of Patent: September 14, 2021
    Assignee: Starpharma Pty Ltd.
    Inventors: David Owen, Brian Devlin Kelly
  • Patent number: 11083802
    Abstract: Implantable materials visible under ultrasound may delivered to a selected placement site and biodegrade after a certain period of time. Ultrasound visible implantable materials may be delivered through an applicator and may include ultrasound contrast agents and/or radiopaque agents. Applications include monitoring the delivery of an implant of the implantable materials to the placement site with ultrasound and delivery of therapeutic agents to a tissue at the placement site for treating a patient.
    Type: Grant
    Filed: March 12, 2020
    Date of Patent: August 10, 2021
    Assignee: Incept, LLC
    Inventors: Patrick Campbell, Amarpreet S. Sawhney
  • Patent number: 11052053
    Abstract: A nanoparticle includes a core. The core includes a bio-resorbable polyester and a hydrophilic polymer. The hydrophilic polymer is a portion of the bio-resorbable polyester or a separate polymer. An acylated human lactoferrin-derived peptide is coated onto the core. The acylated human lactoferrin-derived peptide is a peptide with the amino acid sequence SEQ ID NO. 1: KCFQWQRNMRKVRGPPVSCIKR or an amino acid sequence, which does not differ by more than 8 amino acid positions from the sequence SEQ ID NO: 1. The N-terminus of the human lactoferrin-derived peptide is acylated with a C16-monoacyl group.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: July 6, 2021
    Assignee: Evonik Operations GmbH
    Inventors: Roland Brock, Rike Nabbefeld, Silko Grimm, Anne Benedikt, Andrea Engel, Alexander Henrik Baron van Asbeck, Jürgen Dieker
  • Patent number: 10966955
    Abstract: Disclosed herein is an ocular drug delivery system, comprising a positively charged chitosan-modified hydrogel, a secretory phospholipase A2 (sPLA2) hydrolysable liposome encapsulating an anti-inflammatory drug and having a negative surface charge, a first thiolated hyaluronic acid (HA-SH) nanoparticle encapsulating a wound-healing drug and having a negative surface charge, and a second HA-SH nanoparticle encapsulating a transforming growth factor-? inhibitor and having a negative surface charge. The sPLA2 hydrolysable liposome and the first and second HA-SH nanoparticles are attached to the positively charged chitosan-modified hydrogel by electrostatic attraction. Uses of the system are also disclosed.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: April 6, 2021
    Assignee: Chang Gung University
    Inventors: Jui-Yang Lai, Li-Jyuan Luo, Chung-Cheng Lo, Duc Dung Nguyen
  • Patent number: 10955419
    Abstract: Methods, systems, compositions and kits are provided for the analysis of target molecules using chromophoric polymer dots conjugated to biomolecules. The use of chromophoric polymer dots improves detection sensitivity and stability when compared with existing techniques. In some aspects, methods, systems, and kits are provided for detecting a target protein using chromophoric polymer dots conjugated to biomolecules in a Western blot analysis. Related methods, systems, compositions and kits are also provided.
    Type: Grant
    Filed: March 5, 2014
    Date of Patent: March 23, 2021
    Assignee: University of Washington
    Inventor: Daniel T. Chiu
  • Patent number: 10940119
    Abstract: In one aspect, methods of preparing composite nanoparticle compositions are described herein. For example, in some embodiments, a method comprises providing a zein solution stream, an organic fluid stream including at least one additive and at least one buffer fluid stream. The zein solution stream, organic fluid stream and buffer fluid stream are delivered to a chamber for mixing at one or more rates sufficient to flash precipitate composite nanoparticles including the additive encapsulated by a shell comprising the zein.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: March 9, 2021
    Assignee: The Trustees of Princeton University
    Inventors: Nikolas T. Weissmueller, Robert K. Prud'Homme
  • Patent number: 10925883
    Abstract: Embodiments of the present invention are directed to a plurality of substantially spherical microspheres comprising at least one API substantially dispersed in at least one polymer and a lyoprotectant on an outside surface of the plurality of substantially spherical microspheres, wherein the plurality of substantially spherical microspheres have a D99[num] particle diameter of less than about 10 m; a D90[num] circularity value of from about 0.8 to about 1.0; and comprise API in a weight of about 20 to about 40 wt. % of the polymer. Other embodiments relate to injectable compositions comprising such microspheres and methods of treating a number of conditions by administering such injectable compositions to a subject.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: February 23, 2021
    Assignee: SpineThera
    Inventors: Jeffrey Missling, Emily R. Rolfes Meyering, Henry Meyer, Celeste Ondich
  • Patent number: 10881609
    Abstract: The present disclosure generally relates to local therapies for the eye and, more particularly, to shaped controlled-release ocular implant devices, including methods for making and using such devices, for delivery of therapeutic agents to the eye. A molded two-layer ocular implant comprises a therapeutic agent for treatment or prevention of a disorder of the eye. The implant comprises a polymer layer and a silicone adhesive layer with a therapeutic agent interspersed therein and joined to the polymer layer. This implant is for placement in the sub-Tenon's space of the eye and provides sustained release of the therapeutic agent during the treatment or prevention of the disorder of the eye.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: January 5, 2021
    Assignee: Retina Foundation Of The Southwest
    Inventor: Karl Csaky
  • Patent number: 10774122
    Abstract: The present disclosure relates to compositions and methods for cancer therapy, including but not limited to, targeted inhibition of cancer markers. In particular, the present disclosure relates to recurrent gene fusions as clinical targets for cancer.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: September 15, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Arul Chinnaiyan, Xiaoju Wang
  • Patent number: 10729702
    Abstract: Provided is a slow release composition to promote bone growth, the slow release composition comprising: an oxysterol encapsulated in a biodegradable polymer to control the release of the oxysterol. Methods of making and use are further provided.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: August 4, 2020
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: David S. Scher, Benjamin T. Reves, Roger E. Harrington, Susan J. Drapeau, Jerbrena C. Jacobs
  • Patent number: 10583091
    Abstract: This invention relates to amphiphile-polymer particles comprising obtaining a first solution comprising a water-insoluble polymer, a payload and a first amphiphile in a water-miscible solvent; mixing the first solution with an aqueous second solution to form an aqueous composition comprising a particle comprising a water-insoluble polymeric core comprising the water-insoluble polymer; the payload; and the first amphiphile.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: March 10, 2020
    Assignees: The Brigham and Women's Hospital, Inc., President and Fellows of Harvard College
    Inventors: Jinjun Shi, Xi Zhu, Omid C. Farokhzad, Xiaoding Xu, Yanlan Liu, Aude Thiriot, Ulrich Von Andrian
  • Patent number: 10577554
    Abstract: Provided herein are various gas-filled particles having a stabilized membrane that encapsulates the gas. Pharmaceutical compositions, methods of use and treatment, and methods of preparation are also described.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 3, 2020
    Assignee: Children's Medical Center Corporation
    Inventors: John Kheir, Brian D. Polizzotti
  • Patent number: 10517934
    Abstract: Compositions and methods for the treatment of skin disorders or disease are provided.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: December 31, 2019
    Assignee: ProTransit Nanotherapy, LLC
    Inventor: Vinod D. Labhasetwar
  • Patent number: 10517910
    Abstract: The present disclosure relates to oncolytic viruses for use transcatheter arterial viroembolization methods. The present disclosure also provides composition with such oncolytic viruses in combination with a biocompatible microparticle or hydrophilic polymer gel agent suitable for active embolization. The present disclosure further provides methods of transcatheter arterial viroembolization using such oncolytic viruses and compositions preferably in a manner that debulks tumor.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: December 31, 2019
    Assignee: SILLAJEN, INC.
    Inventors: Tae Ho Hwang, Nam Hee Lee, Mong Cho, Ungbae Jeon, Doo Jin Byun
  • Patent number: 10463735
    Abstract: The present disclosure concerns a digital corneal crosslinking technology for adjusting the corneal curvature, comprising the following steps: administering in drops a composition comprising a photoinitiator compound to the corneal stromal of the subject, locally irradiating the corneal by utilizing digital micromirror device controlled by computer. The corneal curvature can be adjusted totally or locally. The invention also discloses an apparatus for the digital corneal crosslinking. The method and apparatus is minimum invasive and can be used to accurately and efficiently adjust the corneal curvature.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: November 5, 2019
    Assignee: ZHEJIANG UNIVERSITY
    Inventors: Tao Xie, Jingjun Wu, Qian Zhao, Limei Huang
  • Patent number: 10446782
    Abstract: A quantum dot device includes a first electrode and a second electrode facing each other, a quantum dot layer disposed between the first electrode and the second electrode and comprising a plurality of quantum dots, a first charge auxiliary layer disposed between the first electrode and the quantum dot layer and contacting the quantum dot layer, and a second charge auxiliary layer disposed between the second electrode and the quantum dot layer and contacting the quantum dot layer, wherein the plurality of quantum dots includes a quantum dot including an organic ligand on a surface thereof, the organic ligand including a hydrophilic functional group at a terminal end.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: October 15, 2019
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Moon Gyu Han, Dae Young Chung, Hongkyu Seo, Kwanghee Kim, Kun Su Park, Sujin Park, Eun Joo Jang
  • Patent number: 10434048
    Abstract: A topical sunscreen composition includes metal oxide sunscreen particles, polylactic acid, and a cosmetic carrier in which the metal oxide sunscreen particles and polylactic acid are dispersed. A method of preparing a topical sunscreen composition includes dispersing metal oxide sunscreen particles and polylactic acid in a cosmetic carrier. A method of protecting human skin from ultraviolet (UV) radiation includes applying to human skin a topical sunscreen composition including metal oxide sunscreen particles and polylactic acid dispersed in a cosmetic carrier.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: October 8, 2019
    Assignee: CYBERDERM LABORATORIES INC.
    Inventors: Denis Dudley, Thomas Heinar, Sara Dudley
  • Patent number: 10369537
    Abstract: This present invention provides a spray dryer for use in preparing particles for inhalation, the spray dryer comprising a multi-nozzle apparatus comprising multiple single nozzles suitable for use in preparing inhalation powders and with a drying gas flow rate greater than about 80 kg/h. Also provided is a method for scaling-up a spray drying process for preparing particles for inhalation from a smaller scale spray dryer to a larger scale spray dryer, relative in size to each other, the method comprising the use in the larger scale spray dryer of a multi-nozzle apparatus comprising single nozzles suitable for use in preparing inhalation powders, wherein the number of nozzles in the larger spray dryer is determined by the ratio of the drying gas flow rate of the larger scale spray dryer to the drying gas flow rate of the smaller scale spray dryer.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: August 6, 2019
    Assignee: Hovione Holding Limited
    Inventors: José Luis Santos, Luis Olival, Maria Palha, Filipa Maia, Filipe Neves
  • Patent number: 10369113
    Abstract: The invention provides a nanoparticle composition that is decorated with a urea-based small-molecule peptidomimetic inhibitor of prostate specific membrane antigen (PSMA), which is expressed by almost all solid tumors. This strategy takes advantage of both the avidity of the functionalized nanoparticle for binding to PSMA and the ability of the nanoparticle to be retained for longer periods of time in the tumor due to enhanced leakage via EPR into the tumor interstitium and poor clearance due to underdeveloped or non-existent lymphatics within the tumor.
    Type: Grant
    Filed: July 13, 2016
    Date of Patent: August 6, 2019
    Assignee: The Johns Hopkins University
    Inventors: Sachin S. Chandran, Sangeeta Ray, Martin G. Pomper, Samuel R. Denmeade, Ronnie C. Mease
  • Patent number: 10364474
    Abstract: Disclosed are methods for identifying and/or classifying microbes using one or more single nucleotide polymorphisms (SNPs) in 16S ribosomal RNA (16S rRNA) of prokaryotes and/or one or more SNPs in 5.8S ribosomal RNA (5.8S rRNA) of eukaryotes. Also disclosed are probes, primers and kits that are useful in those methods. Methods for the diagnosis of sepsis based upon these SNPs are also disclosed.
    Type: Grant
    Filed: May 29, 2014
    Date of Patent: July 30, 2019
    Assignee: IMMUNEXPRESS PTY LTD
    Inventors: Richard Bruce Brandon, Flavia Huygens
  • Patent number: 10350222
    Abstract: An injectable, flowable composition, kits that include the same, and methods of medical treatment of a mammal (e.g., human) that include the administration of the same are provided.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: July 16, 2019
    Assignee: SpineThera
    Inventor: Jeffrey Missling
  • Patent number: 10328033
    Abstract: A nanostructured biocompatible wafer for drug delivery to a tissue. The wafer contains a tissue-reactive mucoadhesive polymer and a mesh formed of a plurality of polymer fibers. Also provided is a method for treating an ocular surface disease, disorder, or infection using the nanostructured biocompatible wafer. Additionally, an injectable sustained-release formulation for treating an ocular disorder is disclosed. The formulation includes a drug contained within a plurality of microparticles formed of a biodegradable polymer and are coated with a tissue-reactive compound. Further provided is a method for treating an ocular disorder by injecting the microparticulate sustained release formulation.
    Type: Grant
    Filed: April 3, 2018
    Date of Patent: June 25, 2019
    Assignee: Integral BioSystems LLC
    Inventors: Shikha P. Barman, Moli Liu, Koushik Barman, Kevin L. Ward, Brendan Hackett
  • Patent number: 10307373
    Abstract: Provided is a drug delivery system for control of initial burst of a drug. More particularly, there are provided a drug delivery formulation including: a granule containing a biodegradable polymer and a drug; and a temperature-sensitive hydrogel, and a method for preparing the same. The presently disclosed drug delivery formulation can be prepared via a relatively simple process and allows a drug to be released slowly at a constant rate without initial burst and thus maintains a constant blood level of the drug for a long period of time. Consequently, it is capable of preventing the initial burst of the existing injection-type drug delivery formulations and slow-release granules and providing a desired release profile, including sustained release with time.
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: June 4, 2019
    Assignee: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Moon Suk Kim, Da Yeon Kim
  • Patent number: 10293044
    Abstract: Disclosed are compositions, kits, and methods for improving feed conversion rate in an animal in need thereof. The methods typically comprise administering orally to the animal a composition comprising biodegradable particles, the biodegradable particles comprising a polymer or a co-polymer comprising polylactide (PLA) and having an effective average diameter of 0.5-5 ?m. In the methods, the animal is administered a dose of the biodegradable particles that is effective for improving feed conversion rate in the animal in comparison to an animal that is not administered the composition.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: May 21, 2019
    Assignee: Auburn University
    Inventors: Bernhard Kaltenboeck, Ram B. Gupta, Erfan U. Chowdhury, Courtney A. Ober
  • Patent number: 10285939
    Abstract: The invention relates to compositions and methods that utilize polymeric nanoparticles to deliver a therapeutic compound to ocular cells or ocular tissue. Provided is a drug-loaded micelle comprising self-assembled amphiphilic biopolymers, such as hydrophobically modified nucleic acids or polypeptides, for use as ophthalmic drug delivery system. Also provided are ophthalmic compositions and methods for preventing or treating an ophthalmic disease.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: May 14, 2019
    Assignee: Eberhard Karls Universität Tübingen Medizinische Fakultät
    Inventors: Andreas Herrmann, Jan Willem De Vries, Martin Stephan Spitzer, Sven Oliver Schnichels
  • Patent number: 10286033
    Abstract: The invention provides methods and compositions for use of desmopressin in combination with an alpha-adrenergic receptor antagonist. The methods and compositions are useful in the treatment of nocturia and other urinary frequency disorders.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: May 14, 2019
    Assignee: Serenity Pharmaceuticals, LLC
    Inventors: Seymour H. Fein, Linda Cheng, Maria Cheng, Samuel Herschkowitz
  • Patent number: 10258563
    Abstract: The present invention includes a construct that comprises at least one microbubble encapsulated within the aqueous core of a microcapsule. The present invention also includes a pharmaceutical composition comprising a construct comprising at least one microbubble encapsulated within the aqueous core of a microcapsule. The present invention further includes a method of imaging a tissue or organ in a subject, a method of delivering a therapeutic cargo to a tissue or organ in a subject, and a method of treating a disease or disorder in a subject.
    Type: Grant
    Filed: April 20, 2010
    Date of Patent: April 16, 2019
    Assignee: Drexel University
    Inventors: Steven P. Wrenn, Stephen Dicker
  • Patent number: 10231937
    Abstract: An “inverse” precipitation route to precipitate aqueous soluble species with copolymers as nanoparticles having a hydrophilic, polar core and a less polar shell is described.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: March 19, 2019
    Assignee: The Trustees of Princeton University
    Inventors: Robert F. Pagels, Robert K. Prud'homme
  • Patent number: 10221272
    Abstract: A method of forming a patterned polymer layer on a substrate and a substrate having a polymer layer formed by the method. The method includes providing a substrate comprising a first surface having a first surface energy and a pattern located on the substrate forming a second surface having a second, lower surface energy than the first surface, and selectively depositing a polymeric layer onto the first surface using a monomer material in an initiated chemical vapor deposition process, wherein the initiated chemical vapor deposition process is operated under supersaturation conditions during the deposition process.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: March 5, 2019
    Assignee: DREXEL UNIVERSITY
    Inventors: Kenneth Ka Shun Lau, Sruthi Janakiraman, Chia-Yun Hsieh
  • Patent number: 10195309
    Abstract: A composition comprising polymer particles and a carrier, wherein the polymer particles are a mixture of at least a first polymer and a second polymer, wherein the first polymer is at least partially soluble or dispersible in the carrier, and wherein the polymer particles are arranged such that they can join together to form a scaffold of polymer particles, and wherein the composition is administrable to a human or non-human animal.
    Type: Grant
    Filed: February 1, 2008
    Date of Patent: February 5, 2019
    Assignee: LOCATE THERAPEUTICS LIMITED
    Inventors: Patrick Ginty, Robin Andrew Quirk, Kevin Morris Shakesheff
  • Patent number: 10188658
    Abstract: Described are methods and materials for use in the treatment or prophylaxis of diseases, for example cognitive disorders, using diaminophenothiazines. In particular it relates to treatments having optimized pharmacokinetic properties, and dosage forms are intended to improve the relative cognitive or CNS benefits of the diaminophenothiazines, for instance compared to haematological effects.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: January 29, 2019
    Assignee: WisTa Laboratories Ltd.
    Inventors: Claude Michel Wischik, Damon Jude Wischik, John Mervyn David Storey, Charles Robert Harrington
  • Patent number: 10179190
    Abstract: Methods of treating tissue of a patient, e.g., tissue of an organ such that the bladder, are described. The methods may comprise inserting a medical device within the bladder; and injecting a composition to separate a first layer of tissue from a second layer of tissue. The composition may comprise at least one polysaccharide compound having a concentration ranging from approximately 0.05% to approximately 25% by weight, with respect to the total weight of the composition. The composition may at least partially separate the first layer of tissue from the second layer of tissue. At least one of the first layer of tissue or the second layer of tissue may be a detrusor muscle tissue.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: January 15, 2019
    Assignee: Boston Scientific Scimed, Inc.
    Inventors: Sandra Nagale, David Shreeve, Mark Boden, Jonathan Zoll, Timothy Harrah, Steven Kangas, Kasyap Seethamraju, Deanna Cavallaro, Martin Phelan
  • Patent number: 10179834
    Abstract: The disclosure relates to biodegradable polyether network polymers crosslinked via ester linkages, to substrates, implants and scaffolds comprising the biodegradable polyether network polymers, to methods for preparing such network polymers, implants and scaffolds, and to methods of using substrates, implants and scaffolds comprising the network polymers, particularly for culturing cells and regenerating tissue.
    Type: Grant
    Filed: April 10, 2014
    Date of Patent: January 15, 2019
    Assignee: The University of Melbourne
    Inventors: Anton Blencowe, Berkay Ozcelik, Greg Guanghua Qiao
  • Patent number: 10159743
    Abstract: Non-linear multiblock copolymer-drug conjugates for the treatment and prevention of diseases and disorders of the eye are provided. The polymer-drug conjugates can form nanoparticles, microparticles, and implants that are capable of effectively delivering therapeutic levels of one or more active agents for an extended period of time. Administration to the eye of an active agent in the form of a non-linear multiblock copolymer-drug conjugate produces decreased side effects when compared to administration of the active agent alone. Also provided are methods of treating intraocular neovascular diseases, such as wet age-related macular degeneration as well as diseases and disorders of the eye associated with inflammation, such as uveitis.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: December 25, 2018
    Assignee: The Johns Hopkins University
    Inventors: Jie Fu, Peter A. Campochiaro, Justin Scot Hanes
  • Patent number: 10137088
    Abstract: Provided herein in part is a therapeutic nanoparticle that includes a biocompatible polymer; a polymer—EGFR ligand conjugate, wherein the EGFR ligand is covalently bound directly or through a chemical linker to the polymer, and a therapeutic agent.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: November 27, 2018
    Assignee: Pfizer Inc.
    Inventors: Stephen E. Zale, Kevin Andrew McDonnell, Allen Thomas Horhota
  • Patent number: 10076496
    Abstract: The present invention provides organic nanoparticles that include a molecule having a Log P value of about 3 or above, an amphiphilic diblock copolymer or a surfactant, and a pharmaceutically-acceptable hydrophilic polymer. The present invention also provides methods of making these nanoparticles, e.g., by flash nanoprecipitation, with control over particle size and surface properties. The methods of the present invention provide a means for co-precipitating a water-insoluble compound with an amphiphilic stabilizer within a few milliseconds. The nanoparticles of the present invention exhibit high drug loading, e.g., 50% w/w, and can be produced with a mean particle size less than 200 nm and with a narrow particle size distribution.
    Type: Grant
    Filed: November 9, 2012
    Date of Patent: September 18, 2018
    Assignee: The Chinese University of Hong Kong
    Inventors: Albert Hee Lum Chow, Shing Fung Chow, Xin Ran Zhang, Ka Yee Wan, Kwok Kin Cheng, Lawrence William Baum
  • Patent number: 10064819
    Abstract: Devices, systems, and methods for delivery of an active agent into the eye of a subject can include an intraocular active agent delivery device including an active agent dispersed within a biodegradable active agent matrix. The active agent includes dexamethasone and the delivery device is adapted to fit within a lens capsule or ciliary sulcus of an eye. The delivery device can be inserted into the lens capsule or ciliary sulcus of an eye during cataract surgery or for treatment of uveitis.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: September 4, 2018
    Assignee: University of Utah Research Foundation
    Inventors: Balamurali K. Ambati, Bruce K. Gale, Srinivas Rao Chennamaneni
  • Patent number: 10004790
    Abstract: A method of transdermal delivery of a vaccine, comprising preparing microparticles of encapsulated vaccine by spray drying a mixture of the vaccine and at least one polymer, and injecting the microparticles transdermally using a microneedle delivery apparatus.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: June 26, 2018
    Assignee: THE CORPORATION OF MERCER UNIVERSITY
    Inventor: Martin J. D'Souza
  • Patent number: 9919052
    Abstract: Polyurethane microparticles are derived from structural units comprising poly(alkylene oxide) moieties, caprolactone moieties and urethane moieties. The microparticles may include an active agent and have a particle size from 0.1 to 100 microns. Microparticles for injection have a particle size of 15 to 80 microns; for use as a aerosol 1 to 3 microns; and for intraocular use 0.02 to 2 microns. Dispersivity is in the range 1 to 3.
    Type: Grant
    Filed: June 20, 2012
    Date of Patent: March 20, 2018
    Assignee: Ferring B.V.
    Inventors: Alistair Ross, Jennifer S. Law, Fiona E. McInnes
  • Patent number: 9885808
    Abstract: Coating with photochromic properties, method for producing said coating and use thereof applicable to optical articles and glazed surfaces. The coating is formed by the combination of the following three elements: (1) a polymeric matrix, which is typically rigid and deposited on the surface of interest; (2) hollow, sealed micro- and/or nanocapsules dispersed within said matrix; and (3) solutions of photochromic compounds (chosen from a group comprising spirooxazine, azobenzenes or chromenes) in a liquid solvent that does not react (with the photochromic compound and with the capsule wall), which are encapsulated inside said micro- or nanocapsules.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: February 6, 2018
    Assignee: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS(CSIC)
    Inventors: Jordi Hernando Campos, Claudio Roscini, Nuria Alexandra Vazquez Mera, Daniel Ruiz Molina